\u201cSince then, ALK have been working to improve quality of life for allergy patients whose diseases can severely affect their quality of life,\u201d says Dr. Andrew Hui Siu Fu, general manager, Greater China.<\/span><\/p>\n ALK\u2019s evidence-based allergy immunotherapy products not only reduce allergic symptoms but also treats the underlying cause of a specific allergy. The office of ALK Greater China was set up in 2000 to leverage ALK\u2019s global know-how in allergy diseases management to benefit the allergic patients in Greater China,\u201d explains Hui. <\/span><\/p>\n Allergic disease is one of the world\u2019s most common chronic conditions, affecting millions of people globally, says Hui. \u201cChina is one of the most \u2018un-developed\u2019 allergy markets representing a major growth opportunity for the company. The prevalence of allergic rhinitis and asthma in China are 20% and 5%, corresponding to 260 million and 55 million patients, respectively. ALK has had commercial presence in China since 2005. We are the market leader for allergen specific (mite) subcutaneous immunotherapy with double digit of annual growth. We have more than 150 top ranked hospitals in Greater China who offering ALK\u2019s evidence-based treatment \u2013 Alutard SQ\u00ae.\u201d He adds that in 2016, the company launched an adrenaline auto-injector – Jext\u00ae for the treatment of severe allergic reactions (anaphylaxis) in Hong Kong. This is also the first life-saving adrenaline auto-injector registered in Hong Kong.<\/span><\/p>\n \u201cAs a constant pioneer in the allergy immunotherapy, we have challenged and pushed the boundaries of allergy treatment so that, today, allergy immunotherapy is entering a new era of evidence-based treatment following the advent of more convenient tablet-based treatments pioneered by ALK. Our evidence-based treatment together with more than 90 years \u2018know-how\u2019 in allergy diseases, helped us to differentiate from other competitors locally and globally.\u201d<\/span><\/p>\n According to Hui, the obstacles in Hong Kong market include the low awareness of the availability of allergen immunotherapy, \u201cand this advanced treatment is non-reimbursable by public hospitals.\u201d Only few famous private hospitals and clinics are offering such treatment with ALK\u2019s evidence-based allergy immunotherapy products. Compared to rest of the world where allergy immunotherapy is reimbursable and the market, well educated, Hong Kong is still lack behind the trend. Patient education, doctor education and professional training are the keys for better adaptation of the treatment. Meanwhile, the launch of Jext\u00ae (life-saving adrenaline auto-injector for severe allergy reaction) has shown sign of success in breaking these boundaries.\u201d<\/span><\/p>\nInnovation First <\/span><\/h3>\n
\n
\u201cPatient education, doctor education and professional training are the keys for better adaptation of the treatment.\u201d –\u00a0Dr. Andrew Hui Siu Fu<\/em><\/span><\/h3>\n<\/blockquote>\n
Market Leader <\/span><\/h3>\n
United in Progress <\/span><\/h3>\n
![\"\"](\"http:\/\/www.mediazone.com.hk\/hkmvc\/wp-content\/uploads\/2017\/08\/hkmvc18_ALKABELLO_logo.jpg\"){kind=logo}
<\/p>\n